14.5 MOUNJARO Use in Combination with Metformin or Basal Insulin, or Both in Pediatric Patients 10 Years of Age and Older with Type 2 Diabetes Mellitus SURPASS-PEDS (NCT05260021) was a 30-week double-blind, placebo-controlled trial with a 22-week open-label extension that randomized 99 pediatric patients 10 years of age and older with type 2 diabetes mellitus with inadequate glycemic control on metformin (69%), or basal insulin (8%), or both (23%) to receive subcutaneous MOUNJARO 5 mg, MOUNJARO 10 mg, or placebo once weekly as add-on therapy
Whether youre starting on semaglutide, considering microdosing, or planning a long-term regimen, understanding the dosing strategies is key to maximizing its benefits while minimizing side effects
Glutathione injections can work wonders on your skin
Una buena prctica es mantener actualizado el software del dispositivo, habilitar la verificacin en dos pasos y revisar peridicamente los permisos otorgados a la aplicacin, fortaleciendo as la capa de seguridad personal sin sacrificar usabilidad